-

As 340B Grows More Complex, Covered Entities Need Clearer Visibility Across Vendor Relationships, Contract Pharmacy Arrangements, Manufacturer Restrictions, Referral Activity, and Emerging IRA/MFP Requirements

WILLIAMSON, W.Va.--(BUSINESS WIRE)--Halo340B today called on Federally Qualified Health Centers and other 340B covered entities to take a more strategic and mission-driven approach to understanding their 340B gross-to-net performance.

For covered entities, gross-to-net should be viewed as the difference between the total 340B opportunity available to the organization and the net value actually retained for reinvestment into patient care. That net value can be affected by missed eligible claims, referral capture gaps, contract pharmacy arrangements, TPA and administrative fees, manufacturer restrictions, claims-data submission requirements, duplicate-discount controls, audit risk, and emerging IRA/MFP drug complexity.

The 340B ecosystem depends on many parties. Contract pharmacies, third-party administrators, pharmacy benefit managers, wholesalers, manufacturers, EHR vendors, pharmacy systems, and data partners all play important roles in the operation of the program. But as the program becomes more complex, covered entities need their own independent line of sight into performance, compliance, economics, and value leakage.

“Vendors are important partners in the 340B ecosystem, but the covered entity ultimately owns the mission, the compliance responsibility, and the obligation to ensure that 340B value supports patient care,” said Jody Gooslin, Founder of Halo340B. “Halo340B was built to give covered entities the visibility and operating intelligence they need to understand what is happening across their 340B program, identify leakage, and respond quickly when market or policy changes occur.”

Better insight allows for better and improved oversight in all aspects of a covered entity’s program. Manufacturer contract pharmacy restrictions continue to evolve. Data-submission expectations are changing. Referral prescription capture remains difficult for many covered entities to validate and operationalize. Medicaid duplicate-discount controls require claim-level accuracy. IRA/MFP drugs introduce new operational and pricing considerations. At the same time, many covered entities rely on multiple vendors and data sources that do not always provide an integrated executive view of the program.

Halo340B is not intended to replace the vendor ecosystem that covered entities depend on. Instead, the platform is designed to work across existing relationships and help covered entities reconcile data, identify exceptions, validate opportunities, and create a more transparent operating view of their 340B program.

"I've worked with enough covered entities to know the problem isn't effort — it's visibility. Halo340B gives leadership teams a single intelligence layer across all their existing vendors, pharmacies, and workflows,” said Holly Russo, 340B Consultant. “The goal is simple: protect your compliance, preserve more 340B value, and stop spending your days chasing down answers that should already be in front of you."

For FQHCs, the issue is especially important. Health centers are mission-driven organizations focused on expanding access, improving outcomes, reducing medication barriers, and serving vulnerable communities. When leadership teams lack visibility into 340B gross-to-net performance, dollars that could support patient care, enabling services, care coordination, medication access, and community health initiatives may be delayed, reduced, or lost.

Halo340B helps covered entities move from fragmented oversight to a more coordinated 340B operating model. The platform supports:

  • Executive visibility into gross opportunity, value leakage, and net retained 340B value
  • Identification of missed 340B-eligible claims and revenue opportunities
  • Referral capture and validation support
  • Manufacturer restriction and data-submission visibility
  • Exception tracking across vendors, pharmacies, and claims sources
  • Audit-ready documentation and compliance workflows
  • Integration with EHR, pharmacy, and 340B program data sources
  • Analytics for CEOs, CFOs, COOs, compliance leaders, and pharmacy teams

“The purpose of 340B is not administrative complexity,” Gooslin added. “The purpose is patient access. Covered entities should have the tools to manage the program with confidence, collaborate effectively with their vendors, and ensure more of the value intended for the safety net remains available for the communities they serve.”

Covered entities interested in evaluating their 340B gross-to-net performance, identifying potential value leakage, or strengthening program oversight can learn more at Halo340B.com.

About Halo340B

Halo340B is an AI-driven healthcare technology platform designed to help FQHCs and other 340B covered entities strengthen compliance, improve operational visibility, identify missed revenue opportunities, and protect resources intended for patient care. Halo340B works across existing vendor relationships, EHR systems, pharmacy systems, claims data, referral workflows, and 340B program operations to help covered entities better understand, manage, and optimize their 340B performance.

Contacts

Media Contact

Jody Gooslin
President & CEO
Halo340B
info@halo340b.com
Halo340B.com

Halo340B


Release Versions

Contacts

Media Contact

Jody Gooslin
President & CEO
Halo340B
info@halo340b.com
Halo340B.com

More News From Halo340B

Halo340B Launches Innovative AI-Powered Platform to Strengthen 340B Compliance and Optimize Revenue for Healthcare Providers

WILLIAMSON, W.Va.--(BUSINESS WIRE)--Today marks the official launch of Halo340B (www.halo340b.com), a next-generation AI technology platform designed to transform how healthcare organizations manage the 340B Drug Pricing Program. By delivering a seamless, automated solution, Halo340B eliminates the complexities of program compliance while uncovering missed opportunities to significantly increase revenue for covered entities. For years, covered entities—including health centers, hospitals, rural...
Back to Newsroom